Attys Get $4.5M Of $22M Aegerion Drug Marketing Settlement

Law360, New York (December 7, 2017, 1:25 PM EST) -- A Massachusetts federal judge on Wednesday awarded $4.45 million in fees to attorneys who secured a $22.25 million settlement to end an investor class action accusing Aegerion Pharmaceuticals Inc. of hiding from shareholders the off-label marketing of the cholesterol drug Juxtapid.

U.S. District Judge Mark L. Wolf awarded the attorneys’ fees, worth 20 percent of the settlement fund, as well as litigation expenses worth $184,526, saying the amounts are “fair and reasonable.”

“Judge Wolf, as always, gave the matter serious, in-depth attention and rendered an appropriate decision,”...
To view the full article, register now.